Randomized, Double-blind, Parallel-group, Placebo-controlled, 52-week, Phase IIb Study to AssessEfficacy and Safety of GLPG1690 on Top of Pirfenidone or Nintedanib in Patients with IdiopathicPulmonary Fibrosis (IPF)

Project: Research project

Project Details

Description

Randomized, Double-blind, Parallel-group, Placebo-controlled, 52-week, Phase IIb Study to Assess Efficacy and Safety of GLPG1690 on Top of Pirfenidone or Nintedanib in Patients with Idiopathic Pulmonary Fibrosis (IPF)
StatusActive
Effective start/end date9/19/189/18/21

Funding

  • GALAPAGOS NV

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.